What's Happening?
Eli Lilly and Co reported a significant 48% increase in revenue for the second quarter of 2026, largely driven by its incretin portfolio, which maintains a strong market presence in the U.S. obesity sector. The company highlighted that its medicines account
for 6 out of 10 total prescriptions in the U.S. obesity market and 7 out of 10 injectable prescriptions. Internationally, the company is experiencing rapid growth, with Mounjaro revenue increasing by 55% in Europe, 30% in Japan, and 93% in China. The Medicare GLP-1 Bridge program, launched on July 1, has expanded coverage to 20 million eligible Americans, increasing access to obesity medicines by 35%. However, the company faces challenges, including a 9% decline in U.S. prices due to increased rebates and discounts, and ongoing litigation with the FDA over the regulatory pathway for retatrutide.
Why It's Important?
Eli Lilly's strong performance underscores the growing demand for obesity treatments and the company's strategic positioning in the incretin market. The expansion of the Medicare GLP-1 Bridge program is particularly significant as it increases access to obesity treatments for millions of Americans, potentially setting a precedent for future healthcare coverage expansions. However, the company's challenges, such as price declines and regulatory hurdles, highlight the complexities of navigating the pharmaceutical market. The litigation with the FDA could delay the approval of new treatments, impacting the company's growth trajectory. Additionally, the company's aggressive M&A activity in vaccines and psychiatry suggests a strategic diversification, though it carries integration risks.
What's Next?
Eli Lilly anticipates a deceleration in revenue growth in the second half of 2026 due to one-time rebate adjustments and seasonal factors. The company is also preparing for the international rollout of Foundayo, with major market launches expected in 2027. The ongoing litigation with the FDA over retatrutide's regulatory pathway remains a critical issue, with a Biologics License Application submission planned for Q1 2027. The company's focus on expanding its prescriber base and increasing consumer awareness of its products will be crucial in maintaining its market position.
